Rate My Professor John Kappler

John Kappler, PhD, is a Distinguished Professor in the Department of Immunology and Microbiology at the University of Colorado Anschutz Medical Campus, School of Medicine, which is part of the University of Colorado at Denver system. He holds an affiliate faculty position in the same department and conducts his primary research at National Jewish Health as a principal investigator in the Kappler-Marrack Laboratory. Kappler's academic interests center on T cell biology, with a focus on T cell receptor (TCR) structure and function, antigen presentation by major histocompatibility complex (MHC) molecules, thymic selection processes, and the development of autoreactive T cells contributing to autoimmune diseases such as type 1 diabetes. His studies also explore immune responses to vaccines, including cancer vaccines, and mechanisms involving Toll-like receptor 7 (TLR7) in autoimmunity, as well as the role of memory CD4 T cells and cytotoxic CD8 T cells.

Kappler has made foundational contributions to immunology through key publications such as 'T cell tolerance by clonal elimination in the thymus' (Cell, 1987), 'T cells can distinguish between allogeneic major histocompatibility complex products on identical, monomorphic molecules' (Nature, 1988), 'The Role of the T Cell Receptor in Positive and Negative Selection of Developing T Cells' (Science, 1991), 'Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse' (PNAS, 2011), 'Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice' (Diabetes Metab Res Rev, 2011), and 'Do MHCII-presented neoantigens drive type-1 diabetes and other autoimmune diseases?' (Cold Spring Harb Perspect Med, 2012). In 2015, he was appointed Interim Scientific Director of the Barbara Davis Center for Childhood Diabetes at the University of Colorado. Kappler's impact on the field is evidenced by prestigious honors, including the Wolf Prize in Medicine (2015) for discoveries concerning the control of T cell numbers and responses, and the Novartis Prize for Immunology (2016) shared with Philippa Marrack for fundamental discoveries about T lymphocyte activation and selection. His research continues to influence strategies for immunotherapy and understanding adaptive immunity.